Search results
Results from the Health.Zone Content Network
Dihydroergotamine (DHE), sold under the brand names D.H.E. 45 and Migranal among others, is an ergot alkaloid used to treat migraines. [ 7 ] It is a derivative of ergotamine. It is administered as a nasal spray or injection and has an efficacy similar to that of sumatriptan. Nausea is a common side effect.
Find patient medical information for dihydroergotamine injection on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings.
Unique identifier. A unique identifier (UID) is an identifier that is guaranteed to be unique among all identifiers used for those objects and for a specific purpose. [1] The concept was formalized early in the development of computer science and information systems. In general, it was associated with an atomic data type.
Diffie–Hellman (DH) key exchange[nb 1] is a mathematical method of securely generating a symmetric cryptographic key over a public channel and was one of the first public-key protocols as conceived by Ralph Merkle and named after Whitfield Diffie and Martin Hellman. [1][2] DH is one of the earliest practical examples of public key exchange ...
Dihydroergotamine can reduce blood flow to many areas of the body, which can be serious. Stop using dihydroergotamine and tell your healthcare provider right away if you have any of the following ...
To administer a DHE injection: Check the DHE ampul (vial) to make sure it’s not cracked, and the liquid isn’t cloudy or discolored. Wipe the top of the ampul with an alcohol wipe and break ...
Each vial contains enough medication to treat a single migraine attack. Do not use more than 4 sprays for a single attack. Before using each nasal spray vial, prime the pump by spraying 4 times ...
Unique Device Identification. The Unique Device Identification (UDI) System is intended to assign a unique identifier to medical devices within the United States, Europe, China, South Korea, Saudi Arabia and Taiwan. [1] It was signed into law in the US on September 27, 2007, as part of the Food and Drug Administration Amendments Act (Section ...